Hikma Pharmaceuticals PLC
Atidarymo kaina
SektoriusSveikatos priežiūra
1,474 -0.81
Apžvalga
Akcijų kainos pasikeitimas
24 val.
Min
1469
Max
1491
Pajamos | 165M |
|---|---|
Pardavimai | 41M 1.7B |
P/E Sektoriaus vid. | 10.771 49.052 |
Pelnas, tenkantis vienai akcijai | 1.07 |
Dividendų pajamingumas | 5.74 |
Pelno marža | 9.698 |
Darbuotojai | 9,400 |
EBITDA | 152M 411M |
Rekomendacijos | Pirkti |
|---|---|
12 mėnesių prognozė | +23.99% upside |
Dividendų pajamingumas Sektoriaus vid. | 5.74% 2.36% |
|---|---|
Kitas uždarbis | 2026-08-06 |
Kita Ex Dividend data | 2026-08-13 |
Rinkos kapitalizacija | -526M 3.1B |
|---|---|
Ankstesnė atidarymo kaina | 1474.81 |
Ankstesnė uždarymo kaina | 1474 |
Naujienos nuotaikos
By Acuity
43%
57%
118 / 342 reitingas Healthcare
Hikma Pharmaceuticals PLC Grafikas
Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.
Apie bendrovę Hikma Pharmaceuticals PLC
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including respiratory, oncology, and pain management. It also offers its products in solid, semi-solid, liquid, and injectable final dosage forms. The company operates in the United Kingdom, rest of Europe, North America, the Middle East, North Africa, and internationally. Hikma Pharmaceuticals PLC was founded in 1978 and is headquartered in London, the United Kingdom.